Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Taiwania Capital
Deal Size : $17.0 million
Deal Type : Series B Financing
Details : Windgap and its manufacturing partners are commercializing its ANDI® wet/dry autoinjector platforms. The first product using this platform will be epinephrine for the treatment of anaphylaxis.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
July 09, 2021
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Taiwania Capital
Deal Size : $17.0 million
Deal Type : Series B Financing